Failure of enforcement controlled substance laws in health policy for prescribing opiate medications: A painful assessment of morbidity and mortality

American Journal of Therapeutics

Volumn 13, Issue 6, 2006, Pages 527-533

  Miller, Norman S ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Controlled substances; Health policy; Hydrocodine; Laws; Oxycontin

Indexed keywords

ATORVASTATIN; CONJUGATED ESTROGEN; ESOMEPRAZOLE; HYDROCODONE; LANSOPRAZOLE; LEVOTHYROXINE SODIUM; OPIATE; OXYCODONE; PARACETAMOL; RECOMBINANT ERYTHROPOIETIN; SIMVASTATIN;

DEATH; DECISION MAKING; DEPRESSION; DRUG LEGISLATION; DRUG SAFETY; DYSPHORIA; HEALTH CARE POLICY; HUMAN; INJECTION SITE REACTION; INSOMNIA; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; OPIATE ADDICTION; OPIOID INDUCED EMESIS; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UNITED STATES; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; FEDERAL GOVERNMENT; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; LAW ENFORCEMENT; LIABILITY, LEGAL; MALPRACTICE; OPIOID-RELATED DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROFESSIONAL MISCONDUCT; STATE GOVERNMENT; UNITED STATES;

EID: 33751369357     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000212702.94495.25     Document Type: Review

References (37)

1. The CASA National Advisory Commission on Abuse and Diversion of Controlled Prescription Drugs. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the US. The National Center on Addiction and Substance Abuse at Columbia University. Available at: http://www.casacolumbia. org/absolutenm/articlefiles/380-under_the_counter_diversion.pdf, July, 2005.
2. IMS Health, US Top10 Products by Prescription. Available at: http://www.imshealth.com/public/structu. . .content/1,2779,1343-2343-144004,00. ht.
3. Vaczek, D. Pharmacy Times, Top 200 Drugs in 2004. Available at: http://pharmacytimes.com/Article.cfm?Menu=1&ID=2534.
4. Miller NS, Swiney T, Barkin T. Effects of opiate prescription medication dependence and detoxification on pain perceptions and self-reports. Am J Ther. 2006. In press.
5. Controlled Substance Act (21 U.S.C. 811).
6. Almirall N. Medicine and the pharmaceutical industry: a tainted alliance. Michigan Med. 2006;105:10-12.
7. Miller NS, Sheppard LM, Colenla CC, Magen J. Why physicians are unprepared to treat patients who have alcohol and drug-related disorders. Acad Med. 2001;76:410-418.
8. Managing pain. Dispelling the Myth/Video CME Program. Leawood, Kan: American Academy of Family Physicians; January 2003.
9. Michael E, Clark PhD. American Pain Society: Advocacy and Policy. The use of opioids for the treatment of chronic pain: A consensus statement from American Academy of Pain Medicine and American Pain Society. Approved August 20, 1996. Accessed 1/16/2004.
10. National Institute on Drug Abuse, Proceedings of the Community Epidemiology Work Group, vol.-vol (2001).
11. Cordner SM, Drummer OH, Phelan M, et al. A Study of Deaths Involving Oxycodone. Pub (July 1994). Also available at http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi.
12. US Department of Justice, Drugs and Chemicals of Concern, (2002). [herein after USDOJ]. Also available at http://deadversion.usdoj.gov/drugs concern/oxcontin7.htm.
13. National Institute on Drug Abuse. Drugs of Abuse: Prescription Drugs and Pain Medications, (November 1999); also available at: http://www.nida.nih.gov. infofax/PainMed.html
14. Black RG. The chronic pain syndrome. Surg Clin N Am. 1975;55:999-1011.
15. Finlayson RE, Maruta T, Swason DW. Drug abuse and dependency in patients with chronic pain. Mayo Clin Proc. 1979;54:241-244;
16. Floreen AC, Maruta T, Swanson DW, Swenson WM, The Dissatisfied Patient with Chronic Pain, Pain 1977;4:367-378.
17. American Psychiatric Association. Diagnostic Criteria From DSM-IVTR, 2003.
18. Nancy Zuckerbrod, Associated Press; 2004.
19. General Accounting Office [herein after GAO]. Available at: http://www.gao.gov.
20. Purdue Pharma. Available at: http://www.pharma.com/.
21. Howland v. Purdue Pharma L.P., 2003 Ohio 3699; Lexis 3347. (2003).
22. Foster v. Purdue Pharma L.P., 2002 U.S. Dist. (E.D. Ken., 2002); Lexis 8192 (Feb. 2002).
23. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Dependence. 2006 Feb 1:81(2):103-107.
24. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin® and other opioid analgesics in the United States. 2002-2004;6662-6672.
25. Hays LR. A profile of OxyContin addiction. J Addictive Dis. 2004;23:1-9.
26. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths. II. Evidence Toxic Multiple Drug-Drug Inter. 2004;28:217-225.
27. Cone EJ, Fant RV, Rohay JM, et al. Oxycodine involvement in drug abuse deaths: evidence for toxic multiple drug interactions. J Anal Toxicol. 2004;28:616-624.
28. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol. 2003;27:57-67.
29. Gibson AM, Ryan KM, Joranson DE, et al. J Pain Symptom Manage. 2004;28:176-188.
30. Anderson DT, Fritz KL, Muto JJ. Oxycontin: the concept of a ghost pill and the postmortem tissue distribution of oxycodone in 36 cases. J Anal Toxicol. 2002;26:448-459.
31. Dasgupta N, Kramer ED, Zalman MA, et al. 4th: Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2005.
32. Burrows DL, Hagardorn AN, Harlan GC, et al. A fatal drug interaction between oxycodone and clonazepam. J For Sci. 2003;48:683-686.
33. Sees KL, DiMarino ME, Ruediger NK, et al. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother. 2005;19:13-23.
34. Hermos JA, Young MM, Gagnon DR, et al. Characterization of long-term oxycodone/acetaminophen prescriptions in veteran patients. Arch Intern Med. 2004;164:2361-2366.
35. Wolf BC, Lavezzi WA, Sullivan LM, et al. One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. J For Sci. 2005;50:192-195.
36. Miller NS, Greenfeld A. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. Am J Therap. 2004;11(1):26-32.
37. Harris v. Purdue Pharma, L.P., 218 F.D.R. 590, 596 (S.D. Ohio 2003).